The Latest Breaking News from FDA

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend on to treat autoimmune diseases or cancers

Zingerman's Candy Manufactory recalls Peanut Butter Crush and Cashew Cow bars due to undeclared nuts, posing serious allergy risks just before Halloween.

As dog owners, we try to do what’s best for our pets. We spend time and money selecting food that we believe is high-quality. Many of us switched to “grain-free” diets, believing they were more natural or healthier. Then, in 2018, the U.S. Food and Drug Administration (FDA) announced it…

While penny stocks are risky, they also have the potential to deliver outsized gains.

Hong Thai Herbal recalls batch and apologises after Thailand’s food and drug watchdog reveals microbial contamination

Thailand's FDA recalls Hong Thai Herbal Mixed Balm Formula 2 after microbial contamination found in routine tests, prompting regional consumer safety warnings.

There have currently been no reported illnesses as a result of the choking hazard, the FDA reports

The U.S. Food and Drug Administration (FDA) found that devices made at Koninklijke Philips N.V.'s (NYSE:PHG) Bothell, Reedsville, and Nederland facilities were adulterated due to manufacturing, storage, and quality control practices that failed to meet current Good Manufacturing Practice (GMP) standards.

DexCom Inc (NASDAQ:DXCM) is facing renewed scrutiny after three people with diabetes reportedly died following issues with its G7 continuous glucose monitor, according to adverse event filings submitted to the Food and Drug Administration in September.

We like to believe the pills prescribed to us are perfectly safe—that each one has passed through rigorous testing, expert oversight, and endless studies. And for the most part, that’s true. But every now and then, history reminds us that even modern medicine can stumble spectacularly. Some drugs once hailed…

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.